See the associated article on page 617. In the search for effective therapies against central nervous system (CNS) diseases, it is questioned whether sufficient intralesional drug concentrations can be reached on systemic administration. This is especially true for biologicals such as monoclonal
No takes yet. Share an insight, caveat, or question.
Zanten et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: